XBiotech (XBIT) – Company Press Releases
-
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
-
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
-
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
-
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
-
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
-
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
-
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
-
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
-
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
-
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
-
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
-
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
-
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipirac
-
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipirac
-
XBiotech Inks Clinical Manufacturing Deal
-
XBiotech Inks Clinical Manufacturing Deal
-
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
-
FDA Approves XBiotech’s IND in Rheumatology
-
FDA Approves XBiotech’s IND in Rheumatology
-
XBiotech to Launch Novel Candidate Therapy for Stroke
-
XBiotech to Launch Novel Candidate Therapy for Stroke
-
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer
-
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer
-
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
-
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
-
XBiotech Announces Payment of Dividend to Holders of Common Stock
-
XBiotech Announces Payment of Dividend to Holders of Common Stock
-
XBiotech Announces Dividend to Holders of Common Stock
-
XBiotech Announces Dividend to Holders of Common Stock
-
XBiotech Announces Receipt of $75 Million from Sale of Antibody
-
XBiotech Announces Receipt of $75 Million from Sale of Antibody
-
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
-
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
-
French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
-
French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
-
FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
-
FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
-
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
-
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
-
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
-
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
-
XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail
-
XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail
-
XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections
-
XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections
-
XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization
-
XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization
-
XBiotech Discovers COVID-19 Candidate Therapy
-
XBiotech Discovers COVID-19 Candidate Therapy
-
XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy
Back to XBIT Stock Lookup